Bank­ing on Op­di­vo/Yer­voy com­bo, Bris­tol-My­ers Squibb teas­es out Check­mate-227 again at ES­MO

BARCELONA — Some might con­sid­er the dust set­tled on Mer­ck and Bris­tol-My­ers Squibb’s ri­val­ry over front­line lung can­cer, but Bris­tol-My­ers is not giv­ing up with­out an­oth­er pitch for its Op­di­vo/Yer­voy com­bo.

In an­oth­er look at the much re­port­ed Check­mate-227 tri­al, in­ves­ti­ga­tors broke down the me­di­an OS for the com­bo ver­sus chemo alone — a small win in Part 1 that was over­shad­owed by a flop in part 2. While Mer­ck’s dom­i­nant reg­i­men in­volves pair­ing Keytru­da with chemother­a­py, Bris­tol-My­ers won­ders if an I/O-I/O com­bo free of chemo would make a com­pelling case.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.